GSK Consumer Healthcare is pleased to announce that it has closed its transaction with Pfizer Consumer Healthcare in the UK and Ireland, creating a new joint venture under the name GSK Consumer Healthcare.Launched on 27th April 2020, the business, led by Area General Manager Jon Workman, has spent the intervening period working to bring together the two legacy teams and establish GSK Consumer Healthcare as a single operational entity.

The joint venture brings together an array of fantastic brands including Sensodyne, Voltarol, Panadol, Corsodyl, Anadin, Centrum and Nexium. The combined portfolio means GSK strengthens its leading positions in pain relief, respiratory, vitamins, minerals and supplements, and therapeutic oral health categories and cements the company’s position as the world’s number one OTC business.

Workman comments: “We are embarking on a long-term self-care movement with the aim of sustaining a shift in the behaviours of the nation – getting people to think pharmacist first and avoid unnecessary visits to the GP and A&E in the longer term.

“We have reviewed our organisational structures to create a new leadership team, including the appointment of Jon Lewis, previously of Pfizer, as GSK Consumer Healthcare’s new UK Sales Director. Jon is joined by Jo Cooper, who has been appointed as Commercial Excellence Director, setting sales and innovation strategy and working to deliver best in class results for retailers.”

If you want to share your stories and/or experiences with us, please send an email to editor@pharmacy.biz

LEAVE A REPLY